Journal
IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE
Volume 36, Issue 4, Pages 279-291Publisher
CAMBRIDGE UNIV PRESS
DOI: 10.1017/ipm.2018.47
Keywords
-
Categories
Funding
- CME
- NHS Innovations/Janssen-Cilag award
- National Institute for Health Research Collaboration for Leadership in Applied Health Research & Care Funding Scheme
- NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London
Ask authors/readers for more resources
Recovery rates in schizophrenia remain suboptimal with up to one-third resistant to standard treatments, a population prevalence of 0.2%. Clozapine is the only evidenced-based treatment for treatment resistant schizophrenia (TRS), yet there are significant delays in its use or it may not be trialled, potentially impacting the chance of recovery. Better outcomes with earlier use of clozapine may be possible. There is emerging evidence that early treatment resistance is not uncommon from the earliest stages of psychosis. In this review, we provide an update on TRS, its epidemiology and its management, with a specific focus on the optimal use and timing of clozapine and augmentation strategies for the one-third of patients who do not respond to clozapine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available